Clinical and Experimental Gastroenterology最新文献

{"title":"The Role of Nuclear APOBEC Enzymes in Neoplastic Progression of Ulcerative Colitis.","authors":"Lene Alsøe, Stephan Andreas Brackmann, Yan Liu, Anna Berit Wennerström, Qin Ying Esbensen, Sumana Kalyanasundaram, Yohan Lefol, Diana Domanska, Solveig Norheim Andersen, Hilde Loge Nilsen","doi":"10.2147/CEG.S588161","DOIUrl":"10.2147/CEG.S588161","url":null,"abstract":"<p><p>Aberrant expression of the cytidine DNA deaminase AID in enterocytes within inflamed mucosa in ulcerative colitis (UC) patients has been proposed to be involved in progression of UC to colitis-associated colorectal cancer (CA-CRC). Here, we followed the expression of AID and other nuclear cytidine DNA deaminases of the APOBEC family through several stages of progression of UC in a CA-CRC case (UC progressor) and in a cohort of UC progressors and non-progressors. In inflamed and high-grade dysplastic mucosa, <i>AICDA</i> and <i>APOBEC1</i> mRNAs, but not <i>APOBEC3</i>-family enzyme mRNAs, were overexpressed compared to non-inflamed tissue. Immunohistochemical staining did not show expression of AID or APOBEC3 enzymes in the enterocytes, neither in specimens from the CA-CRC case nor in biopsies from the progressor and non-progressor cohort. APOBEC1 was highly expressed in the enterocytes throughout the colorectum from the CA-CRC case and in most biopsies examined from the progressor and non-progressor cohort. The expression was not correlated with the histology of the mucosa or the progression status of the patients. In the CA-CRC case, we identified AID- and APOBEC3-associated mutation signatures in inflamed, high-grade dysplasia and cancer genomes. In conclusion, our findings suggest that AID or other nuclear APOBECs are unlikely to drive the progression of UC to CA-CRC late during course of UC. However, we cannot exclude the possibility that bursts of AID and nuclear APOBEC3 activity may contribute to formation of genome instability in early phases of disease development.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"588161"},"PeriodicalIF":2.6,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Costs, Demographics, and Causative Agents in Patients Hospitalized for Drug Induced Liver Injury: Trends in a Large Academic Healthcare System.","authors":"Megan Kozar, Yunisse Gonzalez, Dina Halegoua-DeMarzio","doi":"10.2147/CEG.S572371","DOIUrl":"10.2147/CEG.S572371","url":null,"abstract":"<p><strong>Purpose: </strong>Drug-induced liver injury (DILI) is an uncommon but potentially life-threatening condition. To date, the burden of DILI on a single, large healthcare system has not been investigated, preventing adequate resource allocation. This study aims to quantify DILI-related healthcare utilization within the Jefferson Health System (JHS) and identify case-related factors associated with high resource requirements; such information is crucial to focus efforts toward resource reduction.</p><p><strong>Patients and methods: </strong>This study characterizes trends of 48 DILI cases within JHS, including demographics, payer status, causative agent, and DILI pattern. These variables were correlated with length of stay (LOS) and cost relating to the treatment encounter. Patient-level observed LOS and cost were then subtracted from their respective expected values from the Vizient Clinical Database, a platform that provides clinical outcome data from more than 1300 healthcare facilities in the United States.</p><p><strong>Results: </strong>Treatment of DILI cases at JHS required higher than expected cost compared to the Vizient Clinical Database. We found high resource utilization in females, those identifying as black, and in cases where the implicated agent was uncertain. Mixed pattern DILI required the highest healthcare utilization, whereas herbal and dietary supplements (HDS) cases were relatively resource minimal.</p><p><strong>Conclusion: </strong>This study indicates that high clinical suspicion of DILI in historically marginalized populations and improved causative agent identification are key to minimizing the healthcare burden of DILI.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"572371"},"PeriodicalIF":2.6,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13070341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Gastrointestinal Endoscopy: Current Advances, Clinical Integration, and Future Directions: A Narrative Review.","authors":"Vipul D Yagnik, Prema Ram Choudhary, Pankaj Garg","doi":"10.2147/CEG.S573930","DOIUrl":"10.2147/CEG.S573930","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) has emerged as a transformative force in gastrointestinal (GI) endoscopy, aiming to enhance diagnostic accuracy, detection rates, and workflow efficiency. With multiple AI-assisted systems now reaching clinical use, there is a growing need to consolidate evidence regarding their performance, applications, and limitations.</p><p><strong>Objective: </strong>To synthesize contemporary evidence from randomized trials, meta-analyses, and real-world studies to provide a clinically oriented overview of the effectiveness, limitations, and implementation challenges of artificial intelligence in gastrointestinal endoscopy, and to identify key translational gaps that justify the need for this updated review.</p><p><strong>Methods: </strong>A structured narrative synthesis of literature from PubMed, Scopus, Web of Science, and manual reference screening (2005-2025) was performed. Evidence was thematically analyzed across major domains including CADe, CADx, upper gastrointestinal neoplasia, capsule endoscopy, quality monitoring, implementation challenges, and real-world performance. Key lessons, translational barriers, and future research priorities were extracted. Quantitative performance estimates were derived from representative randomized controlled trials and meta-analyses and are presented as reported ranges rather than pooled analyses.</p><p><strong>Results: </strong>CADe systems have demonstrated a consistent 15-20% relative increase in adenoma detection rate (ADR) compared to conventional colonoscopy. CADx algorithms achieve >90% accuracy in differentiating neoplastic from non-neoplastic polyps, supporting \"resect-and-discard\" strategies. AI tools in upper GI endoscopy achieve diagnostic accuracies of 88-96% for early esophageal and gastric neoplasia, outperforming non-expert endoscopists. Despite these benefits, barriers persist-dataset bias, lack of generalizability, medicolegal ambiguity, and regulatory inconsistency.</p><p><strong>Conclusion: </strong>AI has proven efficacy in improving detection and diagnostic precision in GI endoscopy. Future progress requires multicenter validation, standardized datasets, ethical frameworks, and clinician training to enable equitable, safe, and evidence-based integration into routine clinical practice.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"573930"},"PeriodicalIF":2.6,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147580655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Integrated Care for Neurogastroenterology and Motility Disorders: A Model for Clinical Practice.","authors":"Fleur H C Veldman, Kim W E Sweerts, Carsten Leue, Jenny Brouns, Sandra Mulkens, Bo Brans Brabant, Rianne C J Beckers, José M Conchillo, Daniel Keszthelyi","doi":"10.2147/CEG.S581482","DOIUrl":"10.2147/CEG.S581482","url":null,"abstract":"<p><p>Integrated care refers to the coordinated delivery of health services across providers and settings, aimed at ensuring continuous, patient-centered care throughout the course of disease. Models of integrated care have demonstrated particular relevance in the management of gastrointestinal (GI) diseases, such as disorders of gut-brain interaction (DGBI) and inflammatory bowel disease (IBD), due to their multidimensional nature. Integrated care has the potential not only to alleviate symptom burden, but also to improve quality of life and mental health outcomes while reducing healthcare costs. Nevertheless, barriers to implementation persist, and despite growing recognition of its value, integrated care has not yet been systematically adopted for GI motility disorders. These disorders, thought to be multifactorial, exhibit considerable overlap with DGBI, rendering them clinically indistinguishable in some cases. Furthermore, while mental health problems are well recognized in DGBI, they are also commonly observed in individuals with GI motility disorders. In response, Maastricht University Medical Centre+ has developed a multidisciplinary, integrated, patient-centered care model for the diagnosis and management of neurogastroenterology and motility disorders. By presenting this approach, we aim to foster knowledge exchange and support the development of integrated care models adaptable to the specific needs of diverse healthcare settings.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"581482"},"PeriodicalIF":2.6,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13018916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Postoperative Delirium Prediction Model for Patients Undergoing Gastrointestinal Surgery.","authors":"Zhihua Huang, Yang Deng, Qiang Li, Tianran Hu, Xiaoying Xu, Yan Luo","doi":"10.2147/CEG.S534370","DOIUrl":"10.2147/CEG.S534370","url":null,"abstract":"<p><strong>Background: </strong>Postoperative delirium (POD) is a critical and prevalent postoperative complication challenging to major surgeries, associated with the increased morbidity and mortality rate, prolonged hospitalization, and higher healthcare expenditure. Despite the availability of POD prediction tools, none of the models deals particularly with the unique preoperative risks of gastrointestinal surgery patients, which is the critical gap in the present clinical practice. Thus, the objectives of the study were the development and validation of an easy-to-use preoperative prediction model for POD specifically for patients undergoing gastrointestinal surgery, to narrow this gap by a specific population tool.</p><p><strong>Methods: </strong>A total of 369 patients undergoing gastrointestinal surgery were analyzed retrospectively. Univariate analysis was used to identify candidate variables, and a multivariate logistic regression model was built using with statistically significant predictors (P<0.05). The area under the receiver operating characteristic curve (AUC) was used as a measure of model performance. Internal validation was done though 20 times 5-fold cross-validation of the models as a measure of robustness.</p><p><strong>Results: </strong>Univariate analysis identified four statistically significant factors for POD: advanced age (OR = 4.19, 95% CI: 1.68-11.91), lower educational level (OR = 0.25, 95% CI: 0.10-0.60), history of cerebrovascular disease (OR = 6.59, 95% CI: 2.55-16.47), and elevated preoperative serum glucose level (OR = 2.68, 95% CI: 1.03-6.54). All these factors were included in the final POD prediction model, which proved to have strong discriminative power (AUC = 0.810, 95% CI: 0.700-0.921) and good calibration (Hosmer-Lemeshow test, P = 0.436).</p><p><strong>Conclusion: </strong>This model is the first easy-to-use preoperative prediction model of POD particularly developed for gastrointestinal surgical patients and exhibits high discriminatory accuracy. It enables anesthesiologists to promptly stratify the risk of POD, which will allow them to implement preventive interventions in time.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"534370"},"PeriodicalIF":2.6,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12931139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147302968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress on the Adaptation Law and Core Mechanism of Animal Models for Exercise Intervention in Inflammatory Bowel Disease: A Systematic Review.","authors":"Xiwen Yang, Sibin Yi","doi":"10.2147/CEG.S572842","DOIUrl":"10.2147/CEG.S572842","url":null,"abstract":"<p><p>Inflammatory Bowel Disease (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic recurrent intestinal inflammatory disorder with a rising global incidence and younger age trend. Current immunosuppressant-based treatments have limited efficacy due to individual differences, making exercise-a low-cost, safe auxiliary intervention-attractive for improving intestinal inflammation and patient quality of life. However, exercise effects are dually regulated by IBD animal model pathological characteristics and exercise program parameters, with unclear adaptation laws and mechanisms. This PRISMA-compliant systematic review synthesizes evidence from 59 studies (2016-2025, 9 databases) to clarify the \"model-exercise-effect\" correlation. We classified IBD animal models into chemical-induced (DSS/TNBS/OXZ, acute inflammation, suitable for short-term low-intensity active exercise), gene-edited (IL-10 KO/IL-2 KO, chronic genetic susceptibility, requiring long-term moderate-intensity exercise), naturally occurring/microbiota-induced (SAMP1/YitFc/microbiota-transplanted, natural disease course, suitable for microbiota-exercise combined intervention), and emerging models (gnotobiotic/humanized microbiota/organoid, high translational value). Exercise type (active > passive), intensity (50-70% VO₂max optimal), cycle (≥12 weeks for stable microbiota regulation), and timing (preventive > therapeutic in acute phase) significantly affect outcomes. Core mechanisms include intestinal microbiota modulation (increased Lactobacillus/Bifidobacterium, upregulated SCFAs synthesis), inflammatory factor balance (myokines/SCFAs synergistically inhibiting NF-κB), intestinal barrier enhancement (upregulated tight junction proteins), and immune homeostasis remodeling (Treg differentiation/M2 macrophage polarization). Key challenges include model-human pathological differences and exercise protocol standardization. Future research should focus on precise model matching, multi-omics mechanism analysis, and clinical translation to promote exercise as a non-pharmacological intervention for IBD.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"572842"},"PeriodicalIF":2.6,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Proton Pumpopathy Associated with Protein Sorting Machinery: A Narrative Review.","authors":"Aime Patrick Niyomugabo, Leopold Ntakirutimana, Jean Claude Habineza, Abdullateef Isiaka Alagbonsi","doi":"10.2147/CEG.S573016","DOIUrl":"10.2147/CEG.S573016","url":null,"abstract":"<p><strong>Background: </strong>Gastric acid secretion by parietal cells depends on the trafficking and exocytosis of H⁺/K⁺-ATPase-rich tubulovesicles (TVs) to the apical membrane in response to histamine stimulation via cyclic AMP elevation. However, the role of parietal cell's protein sorting machinery [eg, coat protein (COP) II/COP I vesicle proteins, soluble NSF attachment protein receptors (SNAREs), Rab GTPases, clathrin-adaptor proteins, etc.] in the dysregulation of gastric acid homeostasis remains poorly understood. This review synthesizes available evidence on the role of protein sorting machinery in gastric proton pumpopathy, leading to dysregulation of gastric acid secretion.</p><p><strong>Methods: </strong>A thorough search was conducted on PubMed, with Wiley and African Journal Online as supplementary sources, and 15 original research articles published between January 1988 and July 2025 in English were included.</p><p><strong>Results: </strong>Misfolding of α- and β-subunits within the endoplasmic reticulum (ER) results in retention and degradation of the pump, leading to impaired acid secretion. Defective coat protein (COP) II/I vesicular transport disrupts Golgi processing and slows the delivery of proton pumps to tubulovesicles, while impaired Rab GTPase activity interferes with vesicle targeting toward the apical canalicular membrane. Also, dysregulation of SNARE complexes and adaptor proteins prevents effective vesicle docking and fusion, further compromising membrane insertion. In addition, abnormalities in endosomal recycling pathways hinder the retrieval and reinsertion of proton pumps, destabilizing long-term acid secretion.</p><p><strong>Conclusion: </strong>Defects in sorting machinery lead to gastric proton pumpopathy, causing impaired acid secretion. Thus, protein sorting regulators represent promising therapeutic targets to restore proper pump localization, which is a paradigm shift toward disease-modifying therapies that act upstream of the pump, potentially offering solutions for proton pump inhibitor (PPI)-resistant cases and congenital gastric acid disorders.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"573016"},"PeriodicalIF":2.6,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13015958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Results of Extraperitoneal Rectus Abdominis Anterior Sigmoid Colostomy (ERASC) for Prevention of Parastomal Hernia Following Abdominoperineal Resection.","authors":"Haolan Yuan, Xiangshu Li, Zhengqiang Wei","doi":"10.2147/CEG.S557673","DOIUrl":"10.2147/CEG.S557673","url":null,"abstract":"<p><strong>Introduction: </strong>Among patients with rectal cancer undergoing abdominoperineal resection (APR), parastomal hernia (PSH) is the most common long-term complication. Although extraperitoneal colostomy (EPC) has been proposed as an effective surgical method to prevent PSH, its efficacy remains controversial. To effectively reduce the incidence of PSH after APR, we report a new surgical technique-extraperitoneal rectus abdominis anterior sigmoid colostomy (ERASC).</p><p><strong>Objective: </strong>To preliminarily explore the feasibility of extraperitoneal rectus abdominis anterior sigmoid colostomy (ERASC) and its effectiveness in preventing parastomal hernia after abdominoperineal resection (APR).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of patients diagnosed with rectal cancer at the First Affiliated Hospital of Chongqing Medical University from 2022 to 2025, who underwent APR and ERASC. Operative duration, stoma-related complications, re-hospitalizations, and re-operations were recorded and preliminarily analyzed.</p><p><strong>Results: </strong>A total of eight patients met the criteria (six males and two females). Two patients developed incomplete intestinal obstruction during the postoperative hospital stay, both of whom improved after conservative treatment. During a median follow-up of 501 days (IQR 338-618), no stoma-related complications (including but not limited to postoperative stoma obstruction, prolapse, or necrosis) were observed, and none of the eight patients developed a parastomal hernia.</p><p><strong>Conclusion: </strong>Extraperitoneal rectus abdominis anterior sigmoid colostomy (ERASC) has preliminarily demonstrated technical feasibility and long-term effectiveness in preventing PSH in this study.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"557673"},"PeriodicalIF":2.6,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13006352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications.","authors":"Mirkka Koivusalo, Jari Jokelainen, Anna Huhtinen, Bianca Kovac, Saija Silvola, Saku Torvinen, Tero Ylisaukko-Oja, Perttu Arkkila","doi":"10.2147/CEG.S576384","DOIUrl":"10.2147/CEG.S576384","url":null,"abstract":"<p><strong>Objective: </strong>Combining biologicals or Janus kinase inhibitors (JAKis) with conventional medications and switching therapies is common in moderate-to-severe inflammatory bowel disease (IBD) treatment. This study assessed the use of conventional medications, treatment continuation, switching, and factors associated with switching during IBD maintenance therapy with subcutaneous (SC) biologicals or JAKis.</p><p><strong>Materials and methods: </strong>This Finnish nationwide, retrospective registry study included adult Crohn's disease (CD) and ulcerative colitis (UC) patients on SC biological/JAKi maintenance therapy (≥6 months on treatment) during 2003-2023. Pharmacy dispensation data were collected from The Social Insurance Institution.</p><p><strong>Results: </strong>Among 7,707 individuals, use of corticosteroids (CS), immunosuppressants (IS) and 5-aminosalicylates (5-ASA) was less common after SC biological/JAKi initiation. At 24 months, treatment continuation rates were 51-57% for adalimumab, golimumab, ustekinumab and tofacitinib (in UC); and 71-80% for infliximab, vedolizumab and ustekinumab (in CD). Overall, 16% of treatments were switched-most commonly from golimumab (28%), tofacitinib (24%) and adalimumab (21%) to ustekinumab (42% of switches) or vedolizumab (17% of switches). Prior golimumab (adjusted OR, 1.73; 95% CI, 1.42-2.09) or tofacitinib (1.48; 1.16-1.86) use was associated with a higher risk of switching (p<0.001), while prior infliximab (0.12; 0.09-0.16), vedolizumab (0.35; 0.26-0.46), IS (0.52; 0.45-0.57), or 5-ASA (0.62; 0.55-0.70) use was associated with lower risk (p<0.001).</p><p><strong>Conclusion: </strong>Treatment continuation rates during maintenance reached up to 80%. Most switches involved a different mode-of-action. While conventional medications were tapered, IS and 5-ASA may support treatment continuation.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"576384"},"PeriodicalIF":2.6,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report.","authors":"Zhirong Du, Weixun Zhou, Ji Li, Li Ma, Qingli Zhu, Yuxiang Zhi","doi":"10.2147/CEG.S533173","DOIUrl":"10.2147/CEG.S533173","url":null,"abstract":"<p><p>Eosinophilic gastroenteritis (EGE) is a rare, immune-mediated disorder characterized by pathological eosinophilic infiltration of the gastrointestinal tract. Corticosteroids are the primary treatment for EGE, but managing patients who are corticosteroid-dependent can be challenging. This report describes a 33-year-old female patient with EGE and severe hypereosinophilia, who was corticosteroid-dependent and had been on long-term oral corticosteroids for 5 years with an increasing maintenance dose. The patient achieved effective treatment with omalizumab without adverse reactions. This case provides evidence for the efficacy and safety of omalizumab in patients with corticosteroid-dependent eosinophilic gastroenteritis and severe hypereosinophilia.</p>","PeriodicalId":10208,"journal":{"name":"Clinical and Experimental Gastroenterology","volume":"19 ","pages":"533173"},"PeriodicalIF":2.6,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12791163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}